Protecting American Families and Servicemembers from Anthrax Act
- Bill Number
- H.R. 2707
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Armed Forces and National Security
- Status
- Introduced
- Latest Action
- 2025-04-08: Referred to the Committee on Armed Services, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2025-12-24T09:05:14Z
AI-Generated Summary
Purpose
The legislation aims to strengthen U.S. national security and public health by creating a updated, long-term plan to protect against anthrax attacks. Anthrax is a bacterial infection that can be weaponized as a biological threat. The bill focuses on maintaining supplies of medical treatments and preventives (called "countermeasures") to defend civilians, military personnel, and their families.
Key Provisions
- Development of a 10-Year Strategy: Within 180 days of the bill becoming law, the Secretary of Health and Human Services (through the Assistant Secretary for Preparedness and Response) and the Secretary of Defense (through the Assistant Secretary for Nuclear, Chemical, and Biological Defense Programs) must jointly create a modernized strategy. This includes:
- Ensuring ongoing stockpiling and replenishment of anthrax countermeasures to meet required levels.
- Covering stockpiles in the Strategic National Stockpile (a federal reserve of emergency medical supplies) and those held by the Department of Defense (DoD) for civilians, servicemembers, and dependents on military bases.
- Promoting innovative partnerships with manufacturers to sustain production of these countermeasures.
- Reporting Requirements:
- An initial report due within 180 days, submitted to specific congressional committees (covering appropriations, armed services, energy and commerce, and health/labor/pensions). The report must address:
- Threats from weaponized anthrax by foreign nations, designated terrorist groups, or other sources to U.S. people and military sites.
- Federal programs and activities (outside the Public Health Emergency Medical Countermeasures Enterprise, a coordinated biodefense effort) that support the strategy, including budgets, research, procurement, and handling of drug-resistant anthrax strains.
- Efforts to provide countermeasures for military dependents on U.S. bases overseas.
- The strategy itself must be included in this initial report.
- Annual updates to the report thereafter.
- Reports will be classified but may include an unclassified summary section.
- Definitions:
- Anthrax countermeasure: FDA-approved or authorized drugs, devices, or biological products (e.g., antitoxins to neutralize toxins or prophylactics to prevent infection) designed to treat or prevent anthrax.
- Covered Secretaries: Leaders from Health and Human Services and Defense, consulting with biodefense experts.
Significant Changes to Existing Law
- The bill does not directly amend prior laws but builds on frameworks like the Public Health Service Act (which governs the Strategic National Stockpile) and Immigration and Nationality Act (for designating terrorist organizations).
- It introduces a mandatory 10-year planning horizon and annual reporting, which go beyond existing ad-hoc biodefense efforts by requiring a comprehensive, replenishment-focused strategy and explicit inclusion of military dependents abroad.
- Emphasizes sustainability with private manufacturers, potentially shifting from one-time procurements to long-term collaborations.
Potential Impacts
- Government Agencies: The Departments of Health and Human Services and Defense will face new coordination and reporting duties, increasing administrative workload but improving biothreat preparedness. This could lead to higher federal spending on research, procurement, and stockpiling.
- Citizens and Military: Enhances protection for the general public and armed forces against anthrax attacks by ensuring reliable access to treatments, potentially reducing casualties in a biological incident. Military families overseas benefit from targeted supply initiatives.
- International Relations: By addressing threats from foreign states and terrorists, the bill reinforces U.S. biodefense posture, which may influence diplomacy on global biosecurity but does not directly alter foreign policy tools.
Main Stakeholders Affected
- Federal Agencies: Departments of Health and Human Services (especially preparedness office) and Defense (biological defense programs); also involves the Public Health Emergency Medical Countermeasures Enterprise for consultation.
- Private Sector: Manufacturers of anthrax countermeasures, who gain opportunities for sustained partnerships and funding.
- Military and Dependents: Servicemembers, civilians on bases, and families, particularly those abroad, through improved access to protections.
- Congress: Specified committees gain oversight via reports, enabling budget and policy influence.
- General Public: All U.S. residents benefit indirectly from stronger national stockpiles against bioterrorism.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces existing biodefense authorities without creating new regulatory burdens; ensures FDA oversight for countermeasures, maintaining public health standards. Classified reporting aligns with national security protocols under laws like the Atomic Energy Act.
- Constitutional: Supports the federal government's role in defense and public welfare (Article I, Section 8), with no apparent conflicts to individual rights, as it focuses on preparedness rather than surveillance or mandates.
- Political: Promotes bipartisan national security priorities by addressing a specific threat (anthrax, linked to past events like 2001 attacks), potentially fostering inter-agency collaboration. Referred to multiple committees, it may encourage broader congressional debate on biothreat funding amid ongoing global tensions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Davis, Donald G. [D-NC-1]
Cosponsors (18)
Rep. Kiggans, Jennifer A. [R-VA-2], Rep. Ross, Deborah K. [D-NC-2], Rep. Harrigan, Pat [R-NC-10], Rep. Finstad, Brad [R-MN-1], Rep. Bergman, Jack [R-MI-1], Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Gimenez, Carlos A. [R-FL-28], Rep. Messmer, Mark B. [R-IN-8], Rep. Jacobs, Sara [D-CA-51], Rep. Murphy, Gregory F. [R-NC-3], Rep. Turner, Michael R. [R-OH-10], Rep. Miller-Meeks, Mariannette [R-IA-1], Rep. Houlahan, Chrissy [D-PA-6], Rep. Scott, Austin [R-GA-8], Rep. Kean, Thomas H. [R-NJ-7], Rep. Goodlander, Maggie [D-NH-2], Rep. McGuire, John J. [R-VA-5], Rep. McDonald Rivet, Kristen [D-MI-8]
Recent Actions
- 2025-04-08: Referred to the Committee on Armed Services, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-04-08: Referred to the Committee on Armed Services, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-04-08: Introduced in House
- 2025-04-08: Introduced in House
Bill Versions
- Protecting American Families and Servicemembers from Anthrax Act — issued 2025-04-08 — PDF (5 pages)